IL253896B - in mesinesulfonamides that are npc1 inhibitors for the treatment of Niemann-Pick disease and other liposomal storage disorders - Google Patents

in mesinesulfonamides that are npc1 inhibitors for the treatment of Niemann-Pick disease and other liposomal storage disorders

Info

Publication number
IL253896B
IL253896B IL253896A IL25389617A IL253896B IL 253896 B IL253896 B IL 253896B IL 253896 A IL253896 A IL 253896A IL 25389617 A IL25389617 A IL 25389617A IL 253896 B IL253896 B IL 253896B
Authority
IL
Israel
Prior art keywords
neimann
upregulators
npc1
benzenesulfonamide
lysosomal storage
Prior art date
Application number
IL253896A
Other languages
English (en)
Hebrew (he)
Other versions
IL253896A0 (en
Original Assignee
Icahn School Med Mount Sinai
Nat Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icahn School Med Mount Sinai, Nat Institutes Of Health filed Critical Icahn School Med Mount Sinai
Publication of IL253896A0 publication Critical patent/IL253896A0/en
Publication of IL253896B publication Critical patent/IL253896B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/21Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL253896A 2015-02-11 2017-08-08 in mesinesulfonamides that are npc1 inhibitors for the treatment of Niemann-Pick disease and other liposomal storage disorders IL253896B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562114840P 2015-02-11 2015-02-11
PCT/US2016/017504 WO2016130774A1 (en) 2015-02-11 2016-02-11 Benzenesulfonamide upregulators of npc1 for neimann-pick disease and other lysosomal storage disorders

Publications (2)

Publication Number Publication Date
IL253896A0 IL253896A0 (en) 2017-10-31
IL253896B true IL253896B (en) 2019-09-26

Family

ID=56614815

Family Applications (2)

Application Number Title Priority Date Filing Date
IL253896A IL253896B (en) 2015-02-11 2017-08-08 in mesinesulfonamides that are npc1 inhibitors for the treatment of Niemann-Pick disease and other liposomal storage disorders
IL26881119A IL268811A (en) 2015-02-11 2019-08-21 Benzenesulfonamides that are NPC1 inhibitors for the treatment of Niemann-Pick disease and other leprosy storage disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL26881119A IL268811A (en) 2015-02-11 2019-08-21 Benzenesulfonamides that are NPC1 inhibitors for the treatment of Niemann-Pick disease and other leprosy storage disorders

Country Status (8)

Country Link
US (1) US10239830B2 (enExample)
EP (1) EP3256116B1 (enExample)
JP (1) JP6887389B2 (enExample)
CN (1) CN107949380B (enExample)
AU (1) AU2016219231B2 (enExample)
CA (1) CA2976449C (enExample)
IL (2) IL253896B (enExample)
WO (1) WO2016130774A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111289749B (zh) * 2018-12-10 2023-04-14 北京蛋白质组研究中心 C型1类尼曼-匹克蛋白检测物在制备筛查肝细胞癌产品中的应用
WO2021150695A1 (en) * 2020-01-22 2021-07-29 Icahn School Of Medicine At Mount Sinai Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents
WO2022159566A1 (en) 2021-01-21 2022-07-28 Icahn School Of Medicine At Mount Sinai Benzenesulfonamide agonists of trap1 for treating organ fibrosis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6177447B1 (en) * 1996-07-15 2001-01-23 Universiteit Van Amsterdam Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors
EP1178969B1 (en) * 1998-11-09 2005-07-13 James Black Foundation Limited Gastrin and cholecystokinin receptor ligands
WO2004035545A2 (en) * 2002-10-18 2004-04-29 E.I. Du Pont De Nemours And Company Azolecarboxamide herbicides
NZ587549A (en) 2004-06-24 2012-10-26 Vertex Pharma 6-Amino-indole derivatives and processes for their preparation
US8354427B2 (en) 2004-06-24 2013-01-15 Vertex Pharmaceutical Incorporated Modulators of ATP-binding cassette transporters
US8841483B2 (en) 2006-04-11 2014-09-23 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of voltage-gated sodium channels
US9732067B2 (en) * 2012-06-20 2017-08-15 University Of Kansas Compounds and methods for activating the apoptotic arm of the unfolded protein response
AU2013296170A1 (en) * 2012-08-03 2015-03-12 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Cyclodextrin for the treatment of lysosomal storage diseases
US20140128352A1 (en) * 2012-09-20 2014-05-08 Buck Institute For Research On Aging Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production
EP2823816A1 (en) * 2013-07-09 2015-01-14 Tragex Pharma Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases

Also Published As

Publication number Publication date
EP3256116B1 (en) 2022-08-17
CA2976449C (en) 2022-08-09
JP2018510904A (ja) 2018-04-19
EP3256116A4 (en) 2018-07-11
AU2016219231A2 (en) 2017-09-28
WO2016130774A1 (en) 2016-08-18
CN107949380B (zh) 2021-07-06
IL253896A0 (en) 2017-10-31
AU2016219231A1 (en) 2017-09-28
CA2976449A1 (en) 2016-08-18
EP3256116A1 (en) 2017-12-20
US20180044286A1 (en) 2018-02-15
AU2016219231B2 (en) 2020-08-20
CN107949380A (zh) 2018-04-20
IL268811A (en) 2019-10-31
US10239830B2 (en) 2019-03-26
JP6887389B2 (ja) 2021-06-16

Similar Documents

Publication Publication Date Title
IL266047A (en) Methods and preparations for the treatment of Fabry disease
PT3487505T (pt) Administração e dosagem de diaminofenotiazinas
HUE036084T2 (hu) Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél
PT3412660T (pt) Derivado de sulfonamida e composição farmacêutica contendo o mesmo
IL266132B (en) Pharmaceutical formulations and methods for their preparation
ZA201902090B (en) Combination treatments comprising administration of imidazopyrazinones
EP3178473C0 (en) ACID-RESISTANT CAPSULE COVER AND PREPARATION METHOD THEREFOR
PT3380525T (pt) Formulações farmacêuticas e métodos que as utilizam
PT3398598T (pt) Derivado de sulfonamida e método de preparação e utilização do mesmo
IL264610A (en) Pharmaceutical compositions and uses directed to lysosomal storage disorders
ZA201606492B (en) Modified sulfamidase and production thereof
IL257932A (en) Adapted cytotoxins and their therapeutic uses
TWI563001B (en) Disintegrin variants and pharmaceutical uses thereof
SG11201604840TA (en) Prophylactic and/or therapeutic agent for functional gastrointestinal disorders
IL268811A (en) Benzenesulfonamides that are NPC1 inhibitors for the treatment of Niemann-Pick disease and other leprosy storage disorders
IL257806A (en) Laxative formulations and manufacture
PL3697392T3 (pl) Tabletki zawierające tamsulosynę i solifenacynę
GB201519644D0 (en) Therapy and pharmaceutical composition
SG11201607074PA (en) Medical pendant box body and post used for medical pendant box body
GB201419354D0 (en) Pharmaceutical extracts and uses thereof
AP2017009817A0 (en) Capsaicinoids and uses thereof as medicaments
GB201612863D0 (en) Administration and dosage of diaminophenothiazines
GB201511863D0 (en) Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same
GB201401314D0 (en) Bernard's theory of software and technology

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed